MediWound to Court Investors with Tissue Repair Pipeline at Key Conferences

YAVNE, Israel – February 17, 2026 – MediWound Ltd. (Nasdaq: MDWD), a biotechnology firm specializing in enzymatic, non-surgical therapies for tissue repair, has announced its management will present at two influential investor conferences in the coming weeks. The presentations at the Oppenheimer 36th Annual Healthcare Life Sciences Conference and the TD Cowen 46th Annual Health Care Conference represent a critical opportunity for the company to articulate its growth strategy and clinical progress to Wall Street.

While such announcements are common in the biotech sector, the timing for MediWound is particularly significant. The company is at a crucial juncture, balancing the commercial expansion of its approved burn treatment, NexoBrid®, with a high-stakes investment in its late-stage pipeline asset, EscharEx®, for chronic wounds. The upcoming presentations will be closely scrutinized by investors and analysts looking for clarity on the company’s path to profitability and its potential to disrupt the multi-billion-dollar wound care market.

Building on Commercial Success with NexoBrid

MediWound's current commercial foundation rests on NexoBrid®, an FDA-approved biologic for the enzymatic removal of eschar, or dead tissue, in severe thermal burns. The product's adoption in the United States, managed by exclusive commercial partner Vericel, has shown encouraging momentum. Vericel reported a 38% year-over-year revenue increase for NexoBrid in the third quarter of 2025, following a 52% year-over-year growth in the second quarter. This growth is supported by a steady increase in the number of U.S. burn centers placing orders, with nearly 60 centers consistently using the product.

To meet this rising demand and prepare for further global expansion, MediWound has completed the commissioning of its expanded manufacturing facility. The expansion is designed to increase production capacity sixfold, a strategic investment poised to support growing global demand pending regulatory reviews expected later in 2026. This demonstrated ability to execute on a commercial strategy and scale production provides a layer of credibility as the company pitches its more ambitious future plans to the investment community.

Revenue from NexoBrid, bolstered by development service contracts with the U.S. Department of Defense, has been a key driver for the company. Total revenues reached $5.4 million in Q3 2025, a 23% increase from the previous year. This commercial progress serves as a vital proof of concept for the company's underlying enzymatic technology.

The High-Stakes Bet on EscharEx

The central pillar of MediWound's future growth story, and a primary focus for investors, is EscharEx®. This investigational therapy is being developed for the debridement of chronic wounds, a significantly larger market than severe burns. The company is currently enrolling patients in a global Phase III study known as VALUE, which is evaluating EscharEx in the treatment of venous leg ulcers (VLUs). The trial, spanning approximately 40 sites in the U.S. and Europe, is expected to reach a key milestone in mid-2026 with a pre-specified interim assessment.

Optimism for the program is fueled by strong Phase II data, which indicated EscharEx's superiority over the current market-leading enzymatic agent, SANTYL® (collagenase), a product with over $370 million in annual sales. By demonstrating faster and more effective debridement, MediWound believes EscharEx has the potential to become a new standard of care.

Underscoring the potential of its pipeline candidate, MediWound has forged strategic research collaborations with a roster of global wound care giants, including Essity, Convatec, Solventum, Mölnlycke, and Kerecis. These partnerships, which support the EscharEx trials, provide significant industry validation and de-risk the development pathway. Looking ahead, the company plans to expand the EscharEx program into other chronic wound types, such as diabetic foot ulcers (DFUs) and pressure ulcers (PUs), further broadening its potential market impact.

Navigating the Financial Landscape of Biotech

Advancing a promising drug through late-stage clinical trials is a capital-intensive endeavor, and MediWound's financial strategy is under the microscope. The company's research and development expenses have climbed, reaching $3.5 million in Q3 2025, largely due to the costs associated with the EscharEx VALUE trial. While the company reported a healthy cash position of $54 million at the end of 2025 with no debt, it continues to operate at a net loss as it invests heavily in its future.

Analysts forecast that MediWound will remain unprofitable for the next three years, making its engagement with the investment community at the Oppenheimer and TD Cowen conferences all the more critical. The company must convince investors that its current cash burn is a necessary investment toward a much larger future return. Wall Street appears cautiously optimistic, with a consensus analyst rating of "Moderate Buy" and an average twelve-month price target of $33.50, suggesting a potential upside of nearly 90% from its current trading price of around $17.77.

However, the stock has been volatile, trading within a 52-week range of $14.14 to $22.50. An increase in short interest in January also suggests some market skepticism. These presentations provide management a platform to directly address these concerns, reinforce confidence among its significant base of institutional shareholders (who own roughly 46.8% of the stock), and attract new long-term investors to fund its ambitious pipeline through to commercialization.

A Strategic Pitch in a Competitive Arena

For a biotechnology company with a market capitalization under $250 million, appearances at premier events like the Oppenheimer and TD Cowen healthcare conferences are more than just an update; they are a strategic imperative. These forums allow MediWound to control its narrative, highlighting its competitive advantages in non-surgical tissue repair and differentiating its enzymatic platform from other advanced wound care technologies.

The presentations will offer a comprehensive look at the company’s two-pronged strategy: maximizing the value of its on-market asset, NexoBrid, while advancing its potential blockbuster, EscharEx. Investors will be listening intently for updates on NexoBrid's global commercial rollout and the timeline for its expanded manufacturing capacity. But all eyes will ultimately be on the progress of the EscharEx Phase III trial, as its success is widely seen as the key catalyst that could unlock significant long-term value for MediWound and its shareholders.